Bayer's Inhaled Cipro Cannot Surmount Inconsistent Efficacy Data At US FDA Panel

Advisory committee recommends against approval of dry powder formulation for treating non-cystic fibrosis bronchiectasis due to inconsistent results in Phase III RESPIRE trials and concerns about long-term benefit and antibiotic resistance.